NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

After years of limping along, the GSK share price has leapt 11% in one month. But one of America's richest investors is ...

These latest developments come just a few weeks after DeepSeek's release of a lower-cost AI model rattled markets, as it sparked concerns about the level of spending by major US tech companies in this ...

Enhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new ...

GSK said its five-in-one meningococcal vaccine Penmenvy was approved by the U.S. Food and Drug Administration. The British pharmaceutical company on Monday said the vaccine was authorized for use in ...

GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals ...